Appian Selected by Accenture as a Core Partner in the INTIENT Network for Life Sciences
Appian (NASDAQ: APPN) has joined Accenture's INTIENT partner ecosystem to enhance collaboration between independent software vendors and life sciences companies. This partnership aims to expedite drug discovery and improve patient outcomes. Appian's low-code automation platform allows for applications to be built up to 20x faster than traditional methods, benefiting productivity and innovation in drug development. The platform will integrate across various INTIENT product suites to deliver improved digital capabilities for life sciences clients.
- Partnership with Accenture enhances Appian's presence in the life sciences sector.
- Low-code platform allows application development up to 20x faster than traditional coding.
- Integrates with multiple INTIENT product suites, expanding market reach.
- None.
MCLEAN, Va., Dec. 15, 2020 /PRNewswire/ -- Appian (NASDAQ: APPN) today announced that it has joined Accenture's INTIENT partner ecosystem as a core partner. The ecosystem is designed to help independent software vendors (ISVs) and life science companies integrate more effectively to accelerate drug discovery efforts and improve patient outcomes.
The INTIENT Network is an integral part of Accenture's INTIENT Platform that enables insights and collaboration across the life sciences enterprise to improve productivity, efficiency, and innovation in drug discovery. Accenture has partnered with Appian to integrate low-code development into the INTIENT platform.
The Appian Low-Code Automation Platform allows enterprises to build applications up to 20x faster than traditional code. By providing a single interface that unifies data, process, people and the digital workforce, Appian helps organizations improve digital innovation and optimize business outcomes. Industry leaders trust Appian to improve customer experience, achieve operational excellence, and simplify global risk management and compliance.
"We are proud to work with Accenture to jointly support research, innovation, and better outcomes for the Life Sciences industry," said Marc Wilson, Founder and Senior Vice President of Global Partnerships and Industries at Appian. "Our ability to accelerate business processes, unify enterprise data, and simplify global compliance is why nine of the world's top 10 drug and biotech organizations use Appian."
As part of the INTIENT partner ecosystem, Appian's platform will be used across the INTIENT Clinical, INTIENT Patient, INTIENT Research, and INTIENT Pharmacovigilance product suites.
"Our open partner network is one of the ways we're bringing innovation to our clients through the Accenture INTIENT platform," said Joe Donahue, a Managing Director in Accenture's Life Sciences practice. "Appian's integration into this ecosystem as a core partner will allow for faster development of new and powerful digital capabilities to drive better results for our Life Sciences customers."
To learn more about Accenture's INTIENT Platform, go to https://www.accenture.com/us-en/services/life-sciences/intient
To request a free trial of the Appian Low-code Automation Platform, go to https://www.appian.com/platform/free-trial/.
About Appian
Appian provides a low-code automation platform that accelerates the creation of high-impact business applications. Many of the world's largest organizations use Appian applications to improve customer experience, achieve operational excellence, and simplify global risk management and compliance. For more information, visit www.appian.com.
View original content:http://www.prnewswire.com/news-releases/appian-selected-by-accenture-as-a-core-partner-in-the-intient-network-for-life-sciences-301191375.html
SOURCE Appian
FAQ
What is Appian's new role in the INTIENT partner ecosystem?
How does Appian's low-code platform benefit drug discovery?
Which companies will benefit from Appian's integration with Accenture's INTIENT platform?
What is the main goal of the INTIENT partner ecosystem?
